Welcome to our dedicated page for Nervgen Pharma news (Ticker: NGENF), a resource for investors and traders seeking the latest updates and insights on Nervgen Pharma stock.
NervGen Pharma Corp. (NGENF) generates news primarily as a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. Newsflow around NervGen often centers on clinical data from its Phase 1b/2a CONNECT SCI Study of its lead candidate NVG-291, regulatory interactions, financing activities, and capital markets developments.
Investors following NGENF news can expect detailed updates on NVG-291’s clinical progress, including topline and expanded data from the chronic cohort of the CONNECT SCI Study and ongoing enrollment in the subacute cohort. Company announcements have highlighted durable improvements in function, independence, and quality of life in individuals with chronic SCI, supported by neurophysiological measures such as changes in corticospinal and reticulospinal signaling. These releases provide insight into how NervGen interprets the efficacy profile and potential impact of NVG-291.
NervGen’s news also covers regulatory milestones, such as FDA Type C meetings and planned End-of-Phase 2 discussions, as well as designations like Fast Track from the FDA and Orphan Drug status from the EMA for spinal cord injury. Capital markets and corporate updates, including non-brokered private placements, at-the-market equity program activity, and the company’s approval for listing on Nasdaq under the symbol NGEN, are additional recurring themes.
Preclinical research updates, particularly Department of Defense–sponsored studies of NVG-291-R in models of traumatic hearing loss and peripheral nerve injury, further contribute to the news stream by illustrating the broader therapeutic potential of NervGen’s technology. For readers tracking NGENF, this news page offers a centralized view of clinical, regulatory, financing, and strategic developments as the company advances its neuroreparative pipeline.
Summary not available.
NervGen Pharma Corp. (TSX-V: NGEN, OTCQX: NGENF) announced a peer-reviewed study showing that its drug NVG-291-R significantly improves motor and sensory functions in rodent models of severe ischemic stroke, even when treatment starts 7 days post-stroke. Currently, there are no FDA-approved treatments that repair stroke damage. NVG-291 is under a Phase 1 clinical trial, with plans for Phase 1b/2 trials targeting spinal cord injury, Alzheimer’s disease, and multiple sclerosis. This research indicates a potential breakthrough in stroke treatment.
NervGen Pharma Corp. (OTCQX: NGENF) has announced its first clinical trial for NVG-291, targeting spinal cord injury patients, through a partnership with Shirley Ryan AbilityLab. This Phase 1b/2a trial will assess the safety and efficacy of NVG-291 in both acute and chronic patients, beginning in late 2022. Previous animal studies published in Nature and Experimental Neurology have shown NVG-291's potential to improve motor and sensory functions significantly. The trial represents a crucial step in translating these promising preclinical results into patient treatment.